Kuros Biosciences AG

EQS-Adhoc: First Trading Day of New Kuros Share after Reverse Split

EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Miscellaneous
First Trading Day of New Kuros Share after Reverse Split

23.06.2016 / 18:31
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

First Trading Day of New Kuros Share after Reverse Split

Schlieren (Zurich), Switzerland, June 23, 2016 - Kuros Biosciences Ltd ("Kuros")
today announced the first trading day of the new shares after a reverse split at
the ratio of 100 to 1 approved by the recent Annual Shareholders' Meeting.

"The reverse split is expected to simplify the trading and increase the shares'
attractiveness for investors", explained Harry Welten, Chief Financial Officer.

Shareholders approved the reverse stock split at the Annual Shareholders'
Meeting on June 16, 2016. 100 existing registered shares with a nominal value of
CHF 0.01 each were exchanged into 1 new (merged) registered share with a nominal
value of CHF 1.00. To allow the allocation of a rounded number of shares,
current shareholders and founders Dr. Jeffrey Hubbell and Didier Cowling
provided the other shareholders for no consideration with the number of shares
required. As a result, each existing shareholder received at least one new
(merged) share and in any event, a rounded number of shares.

For further information, please contact:
Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products for
tissue repair and regeneration and is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the International Reporting
Standard on the SIX Swiss Exchange Ltd under the symbol KURN. Information
regarding Kuros is available atwww.kuros.ch.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider statements
that include the words "will" or "expect" or the negative of those words or
other similar words to be uncertain and forward-looking. Factors that may cause
actual results to differ materially from any future results expressed or implied
by any forward-looking statements include scientific, business, economic and
financial factors, Against the background of these uncertainties, readers should
not rely on forward-looking statements. The Company assumes no responsibility
for updating forward-looking statements or adapting them to future events or


End of ad hoc announcement
Additional features:

Document title: Kuros_Reverse_Split_23062016

23.06.2016 News transmitted by Tensid EQS AG. www.eqs.com

The issuer is responsible for the contents of the release.

Language: English

Company:  Kuros Biosciences AG

          Wagistrasse 25

          8952  Schlieren


Phone:    +41 44 733 4747

Fax:      +41 44 733 4740


Internet: www.kuros.ch

ISIN:     CH0011025217

Valor:    -

Listed:   Foreign Exchange(s) SIX

End of News EQS Group News Service
473985  23.06.2016 

Weitere Meldungen: Kuros Biosciences AG

Das könnte Sie auch interessieren: